Du Laboratories Profile
Key Indicators
- Authorised Capital ₹ 3.00 Cr
as on 16-12-2024
- Paid Up Capital ₹ 2.46 Cr
as on 16-12-2024
- Company Age 17 Year, 15 Days
- Last Filing with ROC 31 Mar 2018
- Open Charges ₹ 4.53 Cr
as on 16-12-2024
- Satisfied Charges ₹ 2.42 Cr
as on 16-12-2024
- Revenue 114.13%
(FY 2018)
- Profit 13825.86%
(FY 2018)
- Ebitda 848.53%
(FY 2018)
- Net Worth 1152.66%
(FY 2018)
- Total Assets 45.98%
(FY 2018)
About Du Laboratories
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2018. It's a company limited by shares with an authorized capital of Rs 3.00 Cr and a paid-up capital of Rs 2.46 Cr.
The company currently has active open charges totaling ₹4.53 Cr. The company has closed loans amounting to ₹2.42 Cr, as per Ministry of Corporate Affairs (MCA) records.
Jitendra Roy, Divakar Goli, Pavagada Ravi, and Six other members serve as directors at the Company.
- CIN/LLPIN
U24232WB2007PLC121073
- Company No.
121073
- Company Classification
Public Limited Indian Non-Government Company
- Incorporation Date
17 Dec 2007
- Date of AGM
28 Sep 2018
- Date of Balance Sheet
31 Mar 2018
- Listing Status
Unlisted
- ROC Code
Roc Kolkata
Industry
Company Details
- Location
Bardhaman, West Bengal, India
- Telephone
- Email Address
- Website
- Social Media
Who are the key members and board of directors at Du Laboratories?
Board Members(9)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Vanishree Beturao  | Director | 02-May-2014 | Current |
| Pavagada Ravi | Director | 02-Jan-2014 | Current |
| Kanhaiya Yadav | Director | 02-Jan-2014 | Current |
| Jitendra Roy | Director | 02-Jan-2014 | Current |
Anish  | Director | 05-May-2014 | Current |
| Divakar Goli | Director | 02-May-2014 | Current |
Financial Performance of Du Laboratories.
Du Laboratories Limited, for the financial year ended 2018, experienced significant growth in revenue, with a 114.13% increase. The company also saw a substantial improvement in profitability, with a 13825.86% increase in profit. The company's net worth Soared by an impressive increase of 1152.66%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Du Laboratories?
In 2018, Du Laboratories had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Canara Bank Creation Date: 25 Jul 2015 | ₹4.53 Cr | Open |
Indian Overseas Bank Creation Date: 28 Mar 2008 | ₹2.42 Cr | Satisfied |
How Many Employees Work at Du Laboratories?
Unlock and access historical data on people associated with Du Laboratories, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Du Laboratories, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Du Laboratories's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
